NCT07100080 2026-04-16
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Phase 2/3 Recruiting
Bristol-Myers Squibb
M.D. Anderson Cancer Center
BioNTech SE
Kaiser Permanente
Medicine Invention Design, Inc
National Cancer Institute (NCI)
Pfizer
Bristol-Myers Squibb
Swiss Cancer Institute